Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

February 15, 2023

Pivonello et al • 2022 • Front. Endocrinol.

Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel

February 12, 2023

Lorusso et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study

February 10, 2023

Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Overall survival data from a 3-arm, randomized, open-label phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer

February 6, 2023

Colombo et al • 2022 • American Society of Clinical Oncology Annual Meeting

Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study

January 27, 2023

Lorusso et al. • 2021 • European Society for Medical Oncology (ESMO) Congress 2021